<DOC>
	<DOCNO>NCT02069119</DOCNO>
	<brief_summary>To investigate safety , pharmacokinetics , efficacy follow 30-minute continuous intravenous administration OPC-108459 0.4 , 0.8 , 1.6 , 2.4 mg/kg placebo patient paroxysmal persistent atrial fibrillation</brief_summary>
	<brief_title>A Trial Determine Safety , Pharmacokinetics , Efficacy OPC-108459 Administered Single Intravenous Dose Patients With Paroxysmal Persistent Atrial Fibrillation ( AF )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Japanese Male female age 20 85 year , inclusive ( time inform consent ) Patients diagnose recent new onset paroxysmal AF ( 3 hour 7 day since onset ) persistent AF ( 8 30 day since onset ) time randomization ( prior Investigational Medicinal Product [ IMP ] administration ) . Review patient 's medical record judgment investigator subinvestigator must document source document establish date duration recent onset AF . Patients receive treatment accord `` Guidelines Pharmacotherapy Atrial Fibrillation ( JCS 2008 ) '' time screen predosing examination low risk thromboembolic potential specify follow : AF last less 48 hour , OR For AF last 48 hour longer : Patients receive warfarin therapy least 3 week elapse since achieve international normalize ratio ( INR ) 2.0 3.0 ( 1.6 2.6 patient age 70 year old ) thrombus atrial main body appendage observe transesophageal echocardiography ( TEE ) within 24 hour IMP administration Patients thrombus atrial main body appendage observe TEE within 24 hour IMP administration undergone antithrombotic therapy undergone antithrombotic therapy ( include new oral antithrombotic drug ) meet criterion Patients systolic blood pressure ( sBP ) 90 mmHg high low 160 mmHg diastolic blood pressure ( dBP ) low 100 mmHg screen examination Female patient postmenopausal least 12 consecutive month , male female patient agree , together partner , practice birth control specify 3 month start IMP administration surgically sterile ( ie , undergone orchiectomy hysterectomy , respectively ) QRS interval &gt; 120 msec Patients heart failure New York Heart Association ( NYHA ) Class II IV leave ventricular ejection fraction ( LVEF ) &lt; 40 % Patients currently history long QT syndrome , torsade de pointes , uncorrected QT interval &gt; 450 msec History ventricular tachycardia , ventricular fibrillation , resuscitate cardiac arrest History AF fail electrical pharmacological cardioversion Current diagnosis atrial flutter Patients bradycardia ( &lt; 50 beat per minute [ bpm ] ) sick sinus syndrome , unless control pacemaker , except physiologically transient sinus bradycardia observe rest sleep Patients WolffParkinsonWhite syndrome Patients congenital severe heart disease Patients severe aortic mitral stenosis ( aorticvalve area , &lt; 1 cm2 ) , severe mitral regurgitation , aortic regurgitation , congenital atrial septal defect , moderate severe pulmonary hypertension , disease lead AF confirm echocardiography within one year prior screen examination Patients diagnose congenital valvular anomaly severe valve disease ( eg , aortic mitral stenosis , severe right leave ventricular systolic dysfunction , severe pulmonary hypertension ) confirm current presence condition TEE screen examination Patients diagnose stroke transient ischemic attack within one year prior screen examination carotid artery stenosis 50 % History myocardial infarction within 6 month prior screen examination Findings acute coronary syndrome , angina , myocardial ischemia diagnose ECG druginduced exercise stress test within 6 month prior screen examination</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>